Lipid raft disruption by docosahexaenoic acid induces apoptosis in transformed human mammary luminal epithelial cells harboring HER-2 overexpression

Journal of Nutritional Biochemistry

Volumn 24, Issue 3, 2013, Pages 505-515

  Ravacci, Graziela Rosa ^a   Brentani, Maria Mitzi ^a   Tortelli, Tharcisio ^a   Torrinhas, Raquel Suzana M M ^a   Saldanha, Tatiana ^b   Torres, Elizabeth Aparecida F S ^a   Waitzberg, Dan Linetzky ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Apoptosis; Cell signaling; Docosahexaenoic acid; HER 2 overexpression; Lipid rafts

Indexed keywords

DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PALMITIC ACID; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; BREAST EPITHELIUM; CARCINOGENESIS; CELL GROWTH; CELL LINE; CELL MEMBRANE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPID RAFT; LIPOGENESIS; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; BREAST; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DOCOSAHEXAENOIC ACIDS; EPITHELIAL CELLS; FEMALE; HUMANS; LIPOGENESIS; MAMMARY GLANDS, HUMAN; MEMBRANE MICRODOMAINS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84875542530     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.02.001     Document Type: Article

References (48)

1. Arribas J., Baselga J., Pedersen K., Parra-Palau J.L. p95HER2 and breast cancer. Cancer Res 2011, 71:1515-1519.
2. Tovey S.M., Brown S., Doughty J.C., Mallon E.A., Cooke T.G., Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100:680-683.
3. Tamimi R.M., Baer H.J., Marotti J., Galan M., Galaburda L., Fu Y., et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:1-9.
4. Bollig-Fischer A., Dziubinski M., Boyer A., Haddad R., Giroux C.N., Ethier S.P. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res 2010, 70:7862-7873.
5. Ghosh R., Narasanna A., Wang S.E., Liu S., Chakrabarty A., Balko J.M., et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011, 71:1871-1882.
6. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
7. Nagy P., Vereb G., Sebestyén Z., Horváth G., Lockett S.J., Damjanovich S., et al. Szöllosi. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci 2002, 115:4251-4262.
8. Simons K., Toomre D. Lipid raft and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
9. Menendez J.A., Vellon L., Lupu R. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypothesis. 2005, 64:997-1001.
10. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-776.
11. Li Y.C., Park M.J., Ye S.K., Kim C.W., Kim Y.N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006, 168:1107-1118.
12. Ayllon V., Fleischer A., Cayla X., Garcia A., Rebollo A. Segregation of bad from lipid rafts is implicated in the induction of apoptosis. J Immunol 2002, 168:3387-3393.
13. Waitzberg D.L., Torrinhas R.S. Fish oil lipid emulsions and immune response: what clinicians need to know. Nutr Clin Pract 2009, 24:487-499.
14. Manzi L., Merendino N., Velotti F., D'Eliseo D., Docosahexaenoic acid inhibits invasion of human RT112 urinary bladder, PT45 pancreatic carcinoma cells via down-modulation of granzyme B expression J Nutr Biochem 2012, 23:452-457.
15. Chamras H., Ardashian A., Heber D., Glaspy J.A. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 2002, 13:711-716.
16. Shaikh S.R., Cherezov V., Caffrey M., Stillwell W., Wassall S.R. Interaction of cholesterol with a docosahexaenoic acid-containing phosphatidylethanolamine: trigger for microdomain/raft formation?. Biochemistry 2003, 42:12028-12037.
17. Menendez J.A., Mehmi I., Atlas E., Colomer R., Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004, 24:591-608.
18. Well W.S., Shaikh S.R., Zerouga M., Siddiqui R., Wassall S.R. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 2005, 45:559-579.
19. Schley P.D., Jijon H.B., Robinson L.E., Field C.J. Mechanisms of omega-3 fatty acid-induced growth in MDA-MB 231 human breast cancer cells. Breast Cancer Res Treat 2005, 92:187-195.
20. Wu M., Harvey K.A., Ruzmetov N., Welch Z.R., Sech L., Jackson K., et al. Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer 2005, 117:340-348.
21. Menendez J.A., Lupu R., Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 2005, 14:263-270.
22. Duncan R.E. EL-Sohemy A, Archer MC. Regulation of HMG-CoA reductase in MCF-7 cells by genestein, EPA, and DHA, alone and in combination with mevastatin. Cancer Lett 2005, 224:221-228.
23. Barascu A., Besson P., Le Floch O., Bougnoux P., Jourdan M.L. CDK1-cyclin B1 mediates the inhibition of proliferation induced by omega-3 fatty acids in MDA-MB-231 breast cancer cells. Int J Biochem Cell Biol 2006, 38:196-208.
24. Khan N.A., Nishimura K., Aires V., Yamashita T., Oaxaca-Castilho D., Kashiwagi K., et al. Docosahexaenoic acid inhibits cancer cell growth via p27kip1, CDK2, ERK1/ERK2, and retinoblastoma phosphorylation. J Lipid Res 2006, 47:2306-2313.
25. Schley P.D., Brindley D.N., Field C.J. (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 2007, 137:548-553.
26. Horia E., Watkins B.A. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 2007, 28:809-815.
27. Hammamieh R., Chakraborty N., Miller S.A., Waddy E., Barmada M., Das R., et al. Differential effects of omega-3 and omega-6 fatty acids on gene expression in breast cancer cells. Breast Cancer Res Treat 2007, 101:7-16.
28. Sun H., Berquin I.M., Owens R.T., O'Flaherty J.T., Edwards I.J. Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 2008, 68:2912-2919.
29. Altenburg J.D., Siddiqui R.A. Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB 231 breast cancer cells. Mol Cancer Res 2009, 7:1013-1020.
30. Ghosh-Choudhury T., Mandal C.C., Woodruff K., St Clair P., Fernandes G., Choudhury G.G., et al. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat 2009, 118:213-228.
31. Rogers K.R., Kikawa K.D., Mouradian M., Hernandez K. M. McKinnon, Ahwah SM, Pardini RS. Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid rafts association. Carcinogenesis 2010, 31:1523-1530.
32. Harris R.A., Eichholtz T.J., Hiles I.D., Page M.J., O'Hare M.J. New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int J Cancer 1999, 80:477-484.
33. Timms J.F., White S.L., O'Hare M.J., Waterfield M.D. Effects of ErbB-2 overexpression on mitogenic signaling and cell cycle progression in human breast luminal epithelial cells. Oncogene 2002, 21:6573-6586.
34. Siddiqui R.A., Jenski L.J., Neff K., Harvey K., Kovacs R.J., Stillwell W. Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta 2001, 1499:265-275.
35. Cury-Boaventura F.M. Cristine Kanunfre C, Gorjão R, Martins de Lima T, Curi R. Mechanisms involved in Jurkat cell death induced by oleic and linoleic acids. Clin Nutr 2006, 25:1004-1014.
36. Folch J., Lees M., Sloane G.H.S. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
37. Wong S.W., Kwon M.J., Choi A.M., Kim H.P., Nakahira K., Hwang D.H. Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem 2009, 284:27384-27392.
38. Jin Q., Yuan L.X., Delphine B., Baek J.M., Wang Y.N., Gomez-Cabello D., et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010, 12:R96.
39. Hilvo M., Denkert C., Lehtinen L., Muller B., Brockmoller S., Seppanen-Laakso T., et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011, 71:3236-3245.
40. Rysman E., Brusselmans K., Scheys K., Timmermans L., Derua R., Munck S., et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 2010, 70:8117-8126.
41. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008, 68:5878-5887.
42. Márquez D.C., Chen H.W., Curran E.M., Welshons W.V., Pietras R.J. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol 2006, 246:91-100.
43. Mocanu M.M., Fazekas Z., Petrás M., Nagy P., Sebestyén Z., Isola J., et al. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett 2005, 227:201-212.
44. Kourtidis A., Jain R., Carkner R.D., Eilfert C., Brosnan M.J., Conklin D.S. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res 2010, 70:1783-1792.
45. Yamaguchi H., Takeo Y., Yoshida S., Kouchi Z., Nakamura Y., Fukami K. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res 2009, 69:8594-8602.
46. Mader C.C., Oser M., Magalhaes M.A., Bravo-Cordero J.J., Condeelis J., Koleske A.J., et al. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res 2011, 71:1730-1741.
47. Sarnataro D., Pisanti S., Santoro A., Gazzero P., Malfitano A.M., Laezza C., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2006, 70:1298-1306.
48. Mollinedo F., de la Iglesia-Vicente J., Gajate C., Estella-Hermoso de Mendoza A., Villa-Pulgarin J.A., Campanero M.A., et al. Lipid raft-targeted therapy in multiple myeloma. Oncogene 2010, 29:3748-3757.